{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:42:33Z","timestamp":1792539753238,"version":"4.5.0"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are commonly used anticoagulants for the management of arterial and venous thromboses. However, it is crucial to be aware that LMWH can, in rare cases, lead to a dangerous complication known as heparin-induced thrombocytopenia (HIT). The objective of this study was to evaluate the pharmacovigilance and clinical features of HIT associated with LMWH, as well as identify treatment strategies and risk factors to facilitate prompt management.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We extracted adverse event report data from the FDA Adverse Event Reporting System (FAERS) database for pharmacovigilance assessment. Case reports on LMWH-induced thrombocytopenia dated up to 20 March 2023 were collected for retrospective analysis.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Significantly elevated reporting rates of HIT were shown in adverse event (AE) data of LMWHs in the FAERS database, while tinzaparin had a higher proportional reporting ratio (PRR) and reporting odds ratio (ROR) than other LMWHs, indicating a greater likelihood of HIT. Case report analysis indicated that a total of 43 patients showed evidence of LMWH-induced thrombocytopenia with a median onset time of 8\u00a0days. Almost half of the events were caused by enoxaparin. LMWHs were mainly prescribed for the treatment of embolism and thromboprophylaxis of joint operation. Patients with a history of diabetes or surgery appeared to be more susceptible to HIT. Clinical symptoms were mostly presented as thrombus, skin lesion, and dyspnea. Almost 90% of the patients experienced a platelet reduction of more than 50% and had a Warkentin 4T score of more than 6, indicating a high likelihood of HIT. In all patients, LMWHs that were determined to be the cause were promptly withdrawn. Following the discontinuation of LMWHs, almost all patients were given alternative anticoagulants and eventually achieved recovery.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> LMWH-induced thrombocytopenia is rare but serious, with increased risk in patients with diabetes or a surgical history. Prompt recognition and management are crucial for the safe use of LMWHs.<\/jats:p>","DOI":"10.3389\/fphar.2023.1247253","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T08:30:34Z","timestamp":1695285034000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Heparin-induced thrombocytopenia associated with low-molecular-weight heparin: clinical feature analysis of cases and pharmacovigilance assessment of the FAERS database"],"prefix":"10.3389","volume":"14","author":[{"given":"Leping","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11239-008-0217-y","article-title":"Platelet factor 4\/heparin antibody (IgG\/M\/A) in healthy subjects: a literature analysis of commercial immunoassay results","volume":"26","author":"Arepally","year":"2008","journal-title":"J. Thromb. Thrombolysis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1182\/blood.v98.4.1252","article-title":"Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8","volume":"98","author":"Arepally","year":"2001","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"6985020","DOI":"10.1155\/2020\/6985020","article-title":"A \"catastrophic\" heparin-induced thrombocytopenia","volume":"2020","author":"Barcellona","year":"2020","journal-title":"Case Rep. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/00000441-200301000-00010","article-title":"Heparin-induced thrombocytopenia with pulmonary embolism and disseminated intravascular coagulation associated with low-molecular-weight heparin","volume":"325","author":"Betrosian","year":"2003","journal-title":"Am. J. Med. Sci."},{"key":"B5","first-page":"A9304","article-title":"Erythema after subcutaneous heparin treatment","volume":"159","author":"Brouns","year":"2015","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"B6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40265-013-0174-4","article-title":"Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism","volume":"74","author":"Burness","year":"2014","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e249685","DOI":"10.1136\/bcr-2022-249685","article-title":"Rare presentation of enoxaparin-induced skin necrosis in a postoperative patient","volume":"15","author":"Byrne","year":"2022","journal-title":"BMJ Case Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/011542650802300116","article-title":"Obesity, inflammation, and the potential application of pharmaconutrition","volume":"23","author":"Cave","year":"2008","journal-title":"Nutr. Clin. Pract."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American society of hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia","volume":"2","author":"Cuker","year":"2018","journal-title":"Blood Adv."},{"key":"B10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1345\/aph.1D308","article-title":"Low-molecular-weight heparin-induced thrombocytopenia in a child","volume":"38","author":"Dager","year":"2004","journal-title":"Ann. Pharmacother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1016\/s2352-3026(18)30046-2","article-title":"Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study","volume":"5","author":"Dhakal","year":"2018","journal-title":"Lancet Haematol."},{"key":"B12","first-page":"135","article-title":"Heparin-induced thrombocytopenia in a patient with lung embolism and left-sided pneumonia: a case report","volume":"58","author":"Doboszy\u0144ska","year":"2007","journal-title":"J. Physiol. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"756.e751","DOI":"10.1016\/j.ajem.2008.10.011","article-title":"Systemic bleeding in a patient with enoxaparin-induced thrombocytopenia","volume":"27","author":"Famularo","year":"2009","journal-title":"Am. J. Emerg. Med."},{"key":"B14","unstructured":"open.fda2023"},{"key":"B15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s12028-009-9320-y","article-title":"Heparin-induced thrombocytopenia and cerebral venous sinus thrombosis: case report and literature review","volume":"15","author":"Fesler","year":"2011","journal-title":"Neurocrit Care"},{"key":"B16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00113-002-0503-7","article-title":"Heparin induced thrombocytopenia type II after the use of low-molecular weight heparin. Case report and review of the literature","volume":"106","author":"Franke","year":"2003","journal-title":"Unfallchirurg"},{"key":"B17","doi-asserted-by":"publisher","first-page":"bcr2017221388","DOI":"10.1136\/bcr-2017-221388","article-title":"Delayed-onset heparin-induced skin necrosis: a rare complication of perioperative heparin therapy","volume":"2017","author":"Gan","year":"2017","journal-title":"BMJ Case Rep."},{"key":"B18","first-page":"545","article-title":"An unusual case of enoxaparin induced thrombocytopenia in intensive care unit","volume":"86","author":"Giuliani","year":"2015","journal-title":"Ann. Ital. Chir."},{"key":"B19","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMcp1411910","article-title":"CLINICAL PRACTICE. Heparin-induced thrombocytopenia","volume":"373","author":"Greinacher","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1160\/TH04-12-0825","article-title":"Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients","volume":"94","author":"Greinacher","year":"2005","journal-title":"Thromb. Haemost."},{"key":"B21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/mbc.0000000000000205","article-title":"Rivaroxaban for arterial thrombosis related to heparin-induced thrombocytopenia","volume":"26","author":"Hantson","year":"2015","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"c143","DOI":"10.1159\/000094959","article-title":"Pseudo-pulmonary embolism as a sign of acute heparin-induced thrombocytopenia in hemodialysis patients: Safety of resuming heparin after disappearance of HIT antibodies","volume":"104","author":"Hartman","year":"2006","journal-title":"Nephron Clin. Pract."},{"key":"B23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/1358863x19898253","article-title":"Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management","volume":"25","author":"Hogan","year":"2020","journal-title":"Vasc. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s00105-010-1999-3","article-title":"Dermal necrosis as cutaneous manifestation of heparin-induced thrombocytopenia II?","volume":"62","author":"Illes","year":"2011","journal-title":"Hautarzt"},{"key":"B25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.medcli.2009.08.007","article-title":"Enoxaparin-induced thrombocytopenia with associated arterial and venous thrombosis","volume":"136","author":"Iturbe","year":"2011","journal-title":"Med. Clin. Barc."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/jth.13003","article-title":"Heparin enhances uptake of platelet factor 4\/heparin complexes by monocytes and macrophages","volume":"13","author":"Joglekar","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/jth.12592","article-title":"Bivalirudin for the treatment of patients with confirmed or suspected heparin-induced thrombocytopenia","volume":"12","author":"Joseph","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"B28","first-page":"A6237","article-title":"Arterial thrombosis due to heparin induced thrombocytopenia","volume":"157","author":"Klinkert","year":"2013","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"B29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4103\/0022-3859.150451","article-title":"A case of probable bemiparin-induced HIT type II managed with low-dose fondaparinux","volume":"61","author":"Koufakis","year":"2015","journal-title":"J. Postgrad. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1182\/blood-2012-06-434985","article-title":"Platelet factor 4 binding to lipid A of Gram-negative bacteria exposes PF4\/heparin-like epitopes","volume":"120","author":"Krauel","year":"2012","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/ccr3.411","article-title":"Apixaban used for the management of heparin-induced thrombocytopenia in a 72-year-old woman with lung cancer","volume":"3","author":"Larsen","year":"2015","journal-title":"Clin. Case Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1080\/16078454.2022.2043572","article-title":"A journey through anticoagulant therapies in the treatment of left ventricular thrombus in post-COVID-19 heparin-induced thrombocytopenia: a case report","volume":"27","author":"L\u00e1zaro-Garc\u00eda","year":"2022","journal-title":"Hematology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.21037\/tcr.2019.09.55","article-title":"Rivaroxaban treatment for cancer-associated venous thromboembolism in a patient with heparin-induced thrombocytopenia: a case report","volume":"8","author":"Le","year":"2019","journal-title":"Transl. Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/jcph.124","article-title":"Efficacy and safety of off-label use of fondaparinux in the management of heparin-induced thrombocytopenia with thrombosis in an elderly woman","volume":"53","author":"Leporini","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e495S","DOI":"10.1378\/chest.11-2303","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Linkins","year":"2012","journal-title":"Chest"},{"key":"B37","doi-asserted-by":"publisher","first-page":"g7566","DOI":"10.1136\/bmj.g7566","article-title":"Heparin induced thrombocytopenia","volume":"350","author":"Linkins","year":"2015","journal-title":"Bmj"},{"key":"B38","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.thromres.2021.09.001","article-title":"Challenging anticoagulation cases: A case of heparin-induced-thrombocytopenia in the first trimester of pregnancy","volume":"207","author":"Lovatt","year":"2021","journal-title":"Thromb. Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1182\/blood-2009-07-231506","article-title":"The severity of trauma determines the immune response to PF4\/heparin and the frequency of heparin-induced thrombocytopenia","volume":"115","author":"Lubenow","year":"2010","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1378\/chest.122.1.37","article-title":"Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin","volume":"122","author":"Lubenow","year":"2002","journal-title":"Chest"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e05297","DOI":"10.1002\/ccr3.5297","article-title":"Rare complication of nadroparin injections: Skin necrosis and heparin-induced thrombocytopenia syndrome","volume":"10","author":"Malinauskiene","year":"2022","journal-title":"Clin. Case Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2146\/ajhp140474","article-title":"Catheter-directed thrombolysis with alteplase and bivalirudin in a patient with heparin-induced thrombocytopenia","volume":"72","author":"Martinez","year":"2015","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1182\/blood-2015-07-660001","article-title":"Reducing the hospital burden of heparin-induced thrombocytopenia: impact of an avoid-heparin program","volume":"127","author":"McGowan","year":"2016","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"E65","DOI":"10.1002\/clc.20546","article-title":"Heparin-induced thrombocytopenia associated with pulmonary embolism","volume":"33","author":"Mumoli","year":"2010","journal-title":"Clin. Cardiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3109\/09537104.2013.779655","article-title":"Heparin-induced thrombocytopenia leading to stroke, lower extremity arterial occlusive disease, and skin necrosis: a case report","volume":"25","author":"Nazliel","year":"2014","journal-title":"Platelets"},{"key":"B46","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/bf02983219","article-title":"Heparin-induced thrombocytopenia: acknowledging its presence in low-molecular weight heparin therapy","volume":"77","author":"Ng","year":"2003","journal-title":"Int. J. Hematol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"101745","DOI":"10.1016\/j.eclinm.2022.101745","article-title":"A machine-learning model for reducing misdiagnosis in heparin-induced thrombocytopenia: A prospective, multicenter, observational study","volume":"55","author":"Nilius","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B48","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American society of hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv."},{"key":"B49","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1742-4801.2005.00121.x","article-title":"Generalised cutaneous necrosis: a complication of low-molecular-weight heparin","volume":"2","author":"Patel","year":"2005","journal-title":"Int. Wound J."},{"key":"B50","doi-asserted-by":"publisher","first-page":"bcr2016215288","DOI":"10.1136\/bcr-2016-215288","article-title":"Nadroparin-induced skin necrosis: clinical manifestation of HIT-2 even in the absence of thrombocytopaenia","volume":"2016","author":"P\u00e9rez","year":"2016","journal-title":"BMJ Case Rep."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1111\/jth.14587","article-title":"The risk of major bleeding in patients with suspected heparin-induced thrombocytopenia","volume":"17","author":"Pishko","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"B52","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/s0168-6054(02)00205-2","article-title":"Heparin induced thrombocytopenia: case report with acute thrombotic complications and literature review","volume":"45","author":"Plassat","year":"2002","journal-title":"Ann. Readapt Med. Phys."},{"key":"B53","doi-asserted-by":"publisher","first-page":"242","DOI":"10.36290\/vnl.2020.068","article-title":"Heparin-induced thrombocytopenia: a case report and literature overview","volume":"66","author":"Pol\u00e1k","year":"2020","journal-title":"Vnitr Lek."},{"key":"B54","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/asheducation-2017.1.667","article-title":"HITs and misses in 100 years of heparin","volume":"2017","author":"Rice","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.4067\/s0034-98872017000901213","article-title":"Treatment of heparin-induced thrombocytopenia with rivaroxaban. Case report","volume":"145","author":"Rivera","year":"2017","journal-title":"Rev. Med. Chil."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1111\/jth.15848","article-title":"Variable serotonin release assay pattern and specificity of PF4-specific antibodies in HIT, and clinical relevance","volume":"20","author":"Rollin","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"B57","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1160\/th07-09-0573","article-title":"Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT)","volume":"99","author":"Rota","year":"2008","journal-title":"Thromb. Haemost."},{"key":"B58","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/JBM.S232648","article-title":"Current perspectives on diagnostic assays and anti-PF4 antibodies for the diagnosis of heparin-induced thrombocytopenia","volume":"11","author":"Sahu","year":"2020","journal-title":"J. Blood Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s11239-015-1208-4","article-title":"Rivaroxaban in the treatment of heparin-induced thrombocytopenia","volume":"40","author":"Sartori","year":"2015","journal-title":"J. Thromb. Thrombolysis"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1111\/j.1538-7836.2010.03795.x","article-title":"Heparin-induced non-necrotizing skin lesions: rarely associated with heparin-induced thrombocytopenia","volume":"8","author":"Schindewolf","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1016\/s0140-6736(12)60409-7","article-title":"Heparin-induced skin lesions","volume":"380","author":"Schindewolf","year":"2012","journal-title":"Lancet"},{"key":"B62","doi-asserted-by":"publisher","first-page":"5275","DOI":"10.3390\/ijms20215275","article-title":"Anticoagulants and osteoporosis","volume":"20","author":"Signorelli","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B63","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00059-013-3908-x","article-title":"Giant thrombus on apical wall of left ventricle due to HIT syndrome after anterior MI","volume":"39","author":"Sinan","year":"2014","journal-title":"Herz"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e922498","DOI":"10.12659\/ajcr.922498","article-title":"Myocardial infarction with limb arterial and venous thrombosis in a patient with enoxaparin-induced thrombocytopenia","volume":"21","author":"Singh","year":"2020","journal-title":"Am. J. Case Rep."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e18757","DOI":"10.7759\/cureus.18757","article-title":"Thrombocytopenia due to direct oral anticoagulation and low-molecular-weight heparin","volume":"13","author":"Tucker","year":"2021","journal-title":"Cureus"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood.v96.5.1703","article-title":"Impact of the patient population on the risk for heparin-induced thrombocytopenia","volume":"96","author":"Warkentin","year":"2000","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/s40064-015-1174-5","article-title":"Heparin-induced thrombocytopenia in a non-heparin-naive patient: a case report","volume":"4","author":"Wiegele","year":"2015","journal-title":"Springerplus"},{"key":"B68","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/RHU.0b013e318258327a","article-title":"Extensive skin necrosis induced by low-molecular-weight heparin in a patient with systemic lupus erythematosus and antiphospholipid syndrome","volume":"18","author":"Yazbek","year":"2012","journal-title":"J. Clin. Rheumatol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.ejim.2003.09.005","article-title":"Severe enoxaparin-induced thrombocytopenia complicated by pulmonary emboli","volume":"14","author":"Zamir","year":"2003","journal-title":"Eur. J. Intern Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1247253\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T08:30:40Z","timestamp":1695285040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1247253\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,20]]},"references-count":69,"alternative-id":["10.3389\/fphar.2023.1247253"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1247253","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,20]]},"article-number":"1247253"}}